TNSN01135A1 - Composes nouveaux inhibiteurs de bcat, procede pour leur preparation et compositions les contenant - Google Patents
Composes nouveaux inhibiteurs de bcat, procede pour leur preparation et compositions les contenantInfo
- Publication number
- TNSN01135A1 TNSN01135A1 TNTNSN01135A TNSN01135A TNSN01135A1 TN SN01135 A1 TNSN01135 A1 TN SN01135A1 TN TNSN01135 A TNTNSN01135 A TN TNSN01135A TN SN01135 A TNSN01135 A TN SN01135A TN SN01135 A1 TNSN01135 A1 TN SN01135A1
- Authority
- TN
- Tunisia
- Prior art keywords
- treating
- disease
- inhibitor compounds
- well
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
- C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSES DE FORMULE (I) : DANS LAQUELLE R1, R2, R3, R4 R5 ET Ar REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION AINSI QUE DES COMPOSITIONS LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, COMME INHIBITEURS DE BCAT, POUR LE TRAITEMENT OU LA PREVENTION DE DIVERSES MALADIES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23378600P | 2000-09-19 | 2000-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN01135A1 true TNSN01135A1 (fr) | 2005-11-10 |
Family
ID=22878678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN01135A TNSN01135A1 (fr) | 2000-09-19 | 2001-09-18 | Composes nouveaux inhibiteurs de bcat, procede pour leur preparation et compositions les contenant |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050004167A1 (fr) |
EP (1) | EP1320523B1 (fr) |
JP (1) | JP2004509880A (fr) |
AT (1) | ATE298323T1 (fr) |
AU (1) | AU2001285067A1 (fr) |
BR (1) | BR0113974A (fr) |
CA (1) | CA2416136A1 (fr) |
DE (1) | DE60111639T2 (fr) |
DO (1) | DOP2001000250A (fr) |
ES (1) | ES2241861T3 (fr) |
GT (1) | GT200100188A (fr) |
MX (1) | MXPA03001277A (fr) |
PA (1) | PA8528901A1 (fr) |
PE (1) | PE20020362A1 (fr) |
TN (1) | TNSN01135A1 (fr) |
UY (1) | UY26939A1 (fr) |
WO (1) | WO2002024672A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02010231A (es) * | 2001-11-27 | 2004-12-13 | Warner Lambert Co | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. |
MXPA02010430A (es) * | 2001-11-27 | 2003-06-02 | Warner Lambert Co | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. |
FR2862646B1 (fr) * | 2003-11-20 | 2006-02-24 | Merck Sante Sas | Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes |
US20080188472A1 (en) * | 2004-03-08 | 2008-08-07 | Prosidion Limited | Indole-2-Carboxylic Acid Hydrazides |
EP2717869B1 (fr) * | 2011-06-13 | 2019-02-27 | Ergon Pharmaceuticals LLC | Méthodes de traitement à l'aide d'un inhibiteur de bcat1 |
US10941109B2 (en) | 2011-06-13 | 2021-03-09 | Ergon Pharmaceuticals Llc | Compositions and methods of treatment using a BCAT1 inhibitor |
WO2017185073A1 (fr) | 2016-04-21 | 2017-10-26 | Eip Pharma, Llc | Compositions et méthodes pour traiter la démence |
US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3606949A1 (de) * | 1986-03-04 | 1987-09-10 | Basf Ag | Chinolinderivate und ihre verwendung zur bekaempfung von unerwuenschtem pflanzenwachstum |
EP0224823A3 (fr) * | 1985-11-26 | 1988-02-10 | BASF Aktiengesellschaft | Dérivés de la quinoléine et leur utilité pour contrôler la croissance non voulue des plantes |
EP0671654B1 (fr) * | 1994-03-11 | 1997-09-10 | Agfa-Gevaert N.V. | Matériau photographique contenant un nouveau type d'hydrazide |
-
2001
- 2001-08-17 AT AT01964182T patent/ATE298323T1/de not_active IP Right Cessation
- 2001-08-17 DE DE60111639T patent/DE60111639T2/de not_active Expired - Fee Related
- 2001-08-17 EP EP01964182A patent/EP1320523B1/fr not_active Expired - Lifetime
- 2001-08-17 ES ES01964182T patent/ES2241861T3/es not_active Expired - Lifetime
- 2001-08-17 BR BR0113974-6A patent/BR0113974A/pt not_active IP Right Cessation
- 2001-08-17 CA CA002416136A patent/CA2416136A1/fr not_active Abandoned
- 2001-08-17 MX MXPA03001277A patent/MXPA03001277A/es not_active Application Discontinuation
- 2001-08-17 WO PCT/US2001/025892 patent/WO2002024672A2/fr active IP Right Grant
- 2001-08-17 AU AU2001285067A patent/AU2001285067A1/en not_active Abandoned
- 2001-08-17 JP JP2002529082A patent/JP2004509880A/ja active Pending
- 2001-09-07 PE PE2001000902A patent/PE20020362A1/es not_active Application Discontinuation
- 2001-09-12 GT GT200100188A patent/GT200100188A/es unknown
- 2001-09-17 UY UY26939A patent/UY26939A1/es not_active Application Discontinuation
- 2001-09-18 TN TNTNSN01135A patent/TNSN01135A1/fr unknown
- 2001-09-19 PA PA20018528901A patent/PA8528901A1/es unknown
- 2001-09-20 DO DO2001000250A patent/DOP2001000250A/es unknown
-
2004
- 2004-01-26 US US10/765,002 patent/US20050004167A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002024672A3 (fr) | 2003-03-06 |
CA2416136A1 (fr) | 2002-03-28 |
DE60111639T2 (de) | 2006-04-27 |
EP1320523A2 (fr) | 2003-06-25 |
US20050004167A1 (en) | 2005-01-06 |
MXPA03001277A (es) | 2004-07-30 |
DE60111639D1 (de) | 2005-07-28 |
ES2241861T3 (es) | 2005-11-01 |
AU2001285067A1 (en) | 2002-04-02 |
BR0113974A (pt) | 2003-07-01 |
DOP2001000250A (es) | 2002-06-15 |
ATE298323T1 (de) | 2005-07-15 |
WO2002024672A2 (fr) | 2002-03-28 |
EP1320523B1 (fr) | 2005-06-22 |
PE20020362A1 (es) | 2002-05-11 |
UY26939A1 (es) | 2002-04-26 |
JP2004509880A (ja) | 2004-04-02 |
GT200100188A (es) | 2002-04-22 |
PA8528901A1 (es) | 2003-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02010231A (es) | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. | |
DK1021418T3 (da) | Substituerede 2,3-benzodiazepin-4-oner og anvendelsen deraf | |
CN113286795A (zh) | 咪唑[1,2-b]哒嗪IL-17A抑制剂 | |
US20090111992A1 (en) | Alkyl ether derivatives or salts thereof | |
DE69514813D1 (en) | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren | |
NZ276892A (en) | Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof | |
TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
IL168723A (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the preparation of medicaments for the treatment of cancer | |
WO1995018616B1 (fr) | 8-aza, 6-aza et 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones et leur utilisation comme antagonistes du recepteur de la glycine ou du nmda | |
TW201326138A (zh) | 犬尿胺酸-3-單氧化酶抑制劑、其醫藥組成物及其使用方法 | |
WO2003027068A3 (fr) | Amines substituees pour le traitement de la maladie d'alzheimer | |
TNSN01135A1 (fr) | Composes nouveaux inhibiteurs de bcat, procede pour leur preparation et compositions les contenant | |
TNSN99227A1 (fr) | Macrolides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
BR9503694A (pt) | Composto método para o tratamento de um mamifero e composição farmacêutica | |
WO2001081309A3 (fr) | 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol | |
CN100406439C (zh) | 作为金属蛋白酶抑制剂的吡咯烷衍生物 | |
KR950704298A (ko) | 신경보호성 3,4-디하이드로-2(1h)-퀴놀론 화합물(neuroprotective 3,4-dihydro-2(1h)-quinolone compounds) | |
MXPA02010430A (es) | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. | |
MY128818A (en) | Ethanesulfonyl-piperidine derivatives | |
EP2673287B1 (fr) | Dérivés d'aminostatine pour le traitement de l'arthrose | |
CA2431761A1 (fr) | Nouveaux derives de 2,3-benzodiazepine et compositions pharmaceutiques contenant lesdits derives comme matiere active | |
CN100497372C (zh) | 酰胺甲基取代的1-(羧烷基)-环戊基羰基氨基-苯并氮杂-n-乙酸衍生物、它们的制备方法和中间产物以及含这些化合物的药物 | |
WO2023150347A3 (fr) | Composés cannabinoïdes synthétiques, compositions pharmaceutiques et méthodes de traitement |